Erqou Sebhat, Kaptoge Stephen, Perry Philip L, Di Angelantonio Emanuele, Thompson Alexander, White Ian R, Marcovina Santica M, Collins Rory, Thompson Simon G, Danesh John
JAMA. 2009 Jul 22;302(4):412-23. doi: 10.1001/jama.2009.1063.
Circulating concentration of lipoprotein(a) (Lp[a]), a large glycoprotein attached to a low-density lipoprotein-like particle, may be associated with risk of coronary heart disease (CHD) and stroke.
To assess the relationship of Lp(a) concentration with risk of major vascular and nonvascular outcomes.
Long-term prospective studies that recorded Lp(a) concentration and subsequent major vascular morbidity and/or cause-specific mortality published between January 1970 and March 2009 were identified through electronic searches of MEDLINE and other databases, manual searches of reference lists, and discussion with collaborators.
Individual records were provided for each of 126,634 participants in 36 prospective studies. During 1.3 million person-years of follow-up, 22,076 first-ever fatal or nonfatal vascular disease outcomes or nonvascular deaths were recorded, including 9336 CHD outcomes, 1903 ischemic strokes, 338 hemorrhagic strokes, 751 unclassified strokes, 1091 other vascular deaths, 8114 nonvascular deaths, and 242 deaths of unknown cause. Within-study regression analyses were adjusted for within-person variation and combined using meta-analysis. Analyses excluded participants with known preexisting CHD or stroke at baseline.
Lipoprotein(a) concentration was weakly correlated with several conventional vascular risk factors and it was highly consistent within individuals over several years. Associations of Lp(a) with CHD risk were broadly continuous in shape. In the 24 cohort studies, the rates of CHD in the top and bottom thirds of baseline Lp(a) distributions, respectively, were 5.6 (95% confidence interval [CI], 5.4-5.9) per 1000 person-years and 4.4 (95% CI, 4.2-4.6) per 1000 person-years. The risk ratio for CHD, adjusted for age and sex only, was 1.16 (95% CI, 1.11-1.22) per 3.5-fold higher usual Lp(a) concentration (ie, per 1 SD), and it was 1.13 (95% CI, 1.09-1.18) following further adjustment for lipids and other conventional risk factors. The corresponding adjusted risk ratios were 1.10 (95% CI, 1.02-1.18) for ischemic stroke, 1.01 (95% CI, 0.98-1.05) for the aggregate of nonvascular mortality, 1.00 (95% CI, 0.97-1.04) for cancer deaths, and 1.00 (95% CI, 0.95-1.06) for nonvascular deaths other than cancer.
Under a wide range of circumstances, there are continuous, independent, and modest associations of Lp(a) concentration with risk of CHD and stroke that appear exclusive to vascular outcomes.
脂蛋白(a)[Lp(a)]是一种附着于低密度脂蛋白样颗粒的大型糖蛋白,其循环浓度可能与冠心病(CHD)和中风风险相关。
评估Lp(a)浓度与主要血管和非血管结局风险之间的关系。
通过对MEDLINE和其他数据库进行电子检索、手动检索参考文献列表并与合作者进行讨论,确定了1970年1月至2009年3月期间发表的记录Lp(a)浓度以及随后主要血管发病率和/或特定病因死亡率的长期前瞻性研究。
为36项前瞻性研究中的126,634名参与者提供了个体记录。在130万人年的随访期间,记录了22,076例首次发生的致命或非致命血管疾病结局或非血管死亡,包括9336例CHD结局、1903例缺血性中风、338例出血性中风、751例未分类中风(译者注:原文为未分类中风,此处根据上下文逻辑进行翻译)、1091例其他血管死亡、8114例非血管死亡以及242例死因不明的死亡。研究内回归分析针对个体内变异进行了调整,并使用荟萃分析进行合并。分析排除了基线时已知患有CHD或中风的参与者。
脂蛋白(a)浓度与几种传统血管危险因素呈弱相关,并且在个体数年内高度一致。Lp(a)与CHD风险的关联在形式上大致呈连续性。在24项队列研究中,基线Lp(a)分布最高和最低三分之一人群中CHD的发生率分别为每1000人年5.6例(95%置信区间[CI],5.4 - 5.9)和每1000人年4.4例(95%CI,4.2 - 4.6)。仅根据年龄和性别调整后,CHD的风险比为每Lp(a)浓度升高3.5倍(即每1个标准差)为1.16(95%CI,1.11 - 1.22),在进一步调整血脂和其他传统危险因素后为1.13(95%CI,1.09 - 1.18)。缺血性中风的相应调整后风险比为1.10(95%CI,1.02 - 1.18),非血管死亡率总体的调整后风险比为1.01(95%CI,0.98 - 1.05),癌症死亡的调整后风险比为1.00(95%CI,0.97 - 1.04),非癌症非血管死亡的调整后风险比为1.00(95%CI,0.95 - 1.06)。
在广泛的情况下,Lp(a)浓度与CHD和中风风险之间存在连续、独立且适度的关联,这些关联似乎仅与血管结局相关。